Table 4.
Percent of Trials Recommending a Dose Level as the MTD and Average Trial Sample Size when the Same TNETS (0.476) is used in all Scenarios.
| Dose level | Percent of Trials Recommending Dose Level d as the MTD | ||||||
|---|---|---|---|---|---|---|---|
| All scenarios (1 to 5) | Scenario 1 | Scenario 2 | Scenario 3 | Scenario 4 | Scenario 5 | ||
| EWOC* | EWOC-NETS** | ||||||
| All 6 dose levels over toxic*** | 0 | 0 | 0 | 0 | 0 | 37 | |
| 1 | 6 | 1 | 0 | 6 | 0 | 59 | |
| 2 | 24 | 12 | 5 | 45 | 0 | 4 | |
| 3 | 46 | 65 | 24 | 42 | 1 | 0 | |
| 4 | 22 | 22 | 65 | 7 | 31 | 0 | |
| 5 | 2 | 0 | 6 | 0 | 65 | 0 | |
| 6 | 0 | 0 | 0 | 0 | 3 | 0 | |
| All 6 dose levels under toxic**** | 0 | 0 | 0 | 0 | 0 | 0 | |
| Sample size Mean (SD) | 25.8 (7.7) | 22.7 (6.1) | 21.9 (4.8) | 23.4 (6.9) | 22.5 (6.6) | 23.4 (5.7) | |
*
EWOC is targeted with TTL ≤ 0.33.
**
EWOC-NETS is targeted with same TNETS for all 5 scenarios.
***
:All the 6 pre-specified dose levels are determined to be over toxic and the recommend MTD from simulation trial is a dose lower than the lowest pre-specified dose level (level 1).
****
: All the 6 pre-specified dose levels are determined to be under toxic and the recommend MTD from simulation trial is a dose higher than the highest pre-specified dose level (level 6).